Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer
- 1 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 28 (5), 2589-2598
- https://doi.org/10.1245/s10434-020-09223-w
Abstract
Background With more effective screening and treatment strategies, there is debate over whether surgical axillary staging should be deescalated for patients with small favorable breast cancers, such as tubular carcinoma (TC). Patients and Methods We identified patients with TC [defined as > 90% tubular tubules (angulated, not multilayered)] and known surgical axillary staging from our institutional database (2000-2018). Using the National Cancer Database (NCDB) (2004-2015), we identified patients with TC, ductal carcinoma in situ (DCIS), and pT1 estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). We determined the rates of lymph node (LN) metastases, and the 5- and 10-year overall survival (OS) for patients with LN-negative versus LN-positive disease using the Kaplan-Meier method and propensity match analysis. Results In our institutional cohort, we identified 112 patients with T1 TC; only one (0.9%) patient had nodal involvement. In the NCDB cohort, we identified 6938 patients with T1 TC; 323 (4.7%) patients had axillary LN disease. The rate of axillary LN involvement for TC was comparable to that identified for patients with DCIS (4.2%), and much lower than that found for patients with grade I-III, T1, ER-positive IDC (20.5%), and patients with grade I, T1, ER-positive IDC (14.4%). There was no difference in 5-year (94.6% versus 95.4%,p = 0.67) and 10-year (83.9% versus 85.2%,p = 0.98) OS between TC patients with or without LN involvement. Kaplan-Meier survival curves even after propensity score matching suggest that tubular histology is independently associated with improved survival. Conclusions T1 TC is an excellent starting point for deescalation of surgical axillary staging.This publication has 28 references indexed in Scilit:
- Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?Annals of Surgical Oncology, 2015
- Axillary Node Interventions in Breast CancerJAMA, 2013
- Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysisThe Lancet Oncology, 2013
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Patient-Reported Outcomes in Sentinel Node–Negative Adjuvant Breast Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32Journal of Clinical Oncology, 2010
- Prevalence of and Factors Associated With Persistent Pain Following Breast Cancer SurgeryJAMA, 2009
- Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the BreastAnnals of Surgery, 2008
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialThe Lancet Oncology, 2007
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI Journal of the National Cancer Institute, 2006
- Tubular carcinoma of the breastCancer, 1978